Amgen Buys KAI Pharmaceuticals

Thousand Oaks-based biotech giant Amgen said this morning that it has agreed to buy KAI Pharmaceuticals, a developer of treatments for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis, for $315M in cash. KAI Pharmaceuticals is based in South San Francisco. Amgen said it gains worldwide rights to KAI's lead compound, excluding Japan. KAI Pharmaceuticals will become a wholly owned subsidiary of Amgen. KAI was venture backed by InterWest Partners, Skyline Ventures, Intersouth Partners, Aberdare Ventures, Investor Growth Capital, Kearny Venture Partners, Lumira Capital and Delphi Ventures.